harvard medical school: "cgrp: a new era for migraine treatment." .
-
.
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
the senate will "hopefully" take up the tobacco bill in june, lewis told the news service. the last day of formal sessions this year is july 31. .
home
-
.